Literature DB >> 19093110

Comment on: Recombinant human TSH in differentiated thyroid cancer: a nuclear medicine perspective.

Markus Luster, Martin Schlumberger, Furio Pacini.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 19093110     DOI： 10.1007/s00259-008-1013-9

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  9 in total

1.  European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium.

Authors:  Furio Pacini; Martin Schlumberger; Henning Dralle; Rossella Elisei; Johannes W A Smit; Wilmar Wiersinga
Journal:  Eur J Endocrinol       Date:  2006-06       Impact factor: 6.664

2.  Recombinant human TSH in differentiated thyroid cancer: a nuclear medicine perspective.

Authors:  Paolo Zanotti-Fregonara; Domenico Rubello; Elif Hindié
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-05-10       Impact factor: 9.236

3.  Thyroid hormone withdrawal in patients with differentiated thyroid carcinoma: a one hundred thirty-patient pilot survey on consequences of hypothyroidism and a pharmacoeconomic comparison to recombinant thyrotropin administration.

Authors:  Markus Luster; Ralph Felbinger; Markus Dietlein; Christoph Reiners
Journal:  Thyroid       Date:  2005-10       Impact factor: 6.568

4.  Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal.

Authors:  Heribert Hänscheid; Michael Lassmann; Markus Luster; Stephen R Thomas; Furio Pacini; Claudia Ceccarelli; Paul W Ladenson; Richard L Wahl; Martin Schlumberger; Marcel Ricard; Al Driedger; Richard T Kloos; Steven I Sherman; Bryan R Haugen; Vincent Carriere; Carine Corone; Christoph Reiners
Journal:  J Nucl Med       Date:  2006-04       Impact factor: 10.057

Review 5.  How the availability of recombinant human TSH has changed the management of patients who have thyroid cancer.

Authors:  Martin Schlumberger; Marcel Ricard; Gérard De Pouvourville; Furio Pacini
Journal:  Nat Clin Pract Endocrinol Metab       Date:  2007-09

6.  Length and cost of hospital stay of radioiodine ablation in thyroid cancer patients: comparison between preparation with thyroid hormone withdrawal and thyrogen.

Authors:  I Borget; H Remy; J Chevalier; M Ricard; M Allyn; M Schlumberger; G De Pouvourville
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-04-02       Impact factor: 9.236

7.  Guidelines for radioiodine therapy of differentiated thyroid cancer.

Authors:  M Luster; S E Clarke; M Dietlein; M Lassmann; P Lind; W J G Oyen; J Tennvall; E Bombardieri
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-10       Impact factor: 9.236

8.  131I effective half-life and dosimetry in thyroid cancer patients.

Authors:  Hervé Remy; Isabelle Borget; Sophie Leboulleux; Nadine Guilabert; Frédéric Lavielle; Jérome Garsi; Claire Bournaud; Séverine Gupta; Martin Schlumberger; Marcel Ricard
Journal:  J Nucl Med       Date:  2008-08-14       Impact factor: 10.057

9.  Sick leave for follow-up control in thyroid cancer patients: comparison between stimulation with Thyrogen and thyroid hormone withdrawal.

Authors:  I Borget; C Corone; M Nocaudie; M Allyn; S Iacobelli; M Schlumberger; G De Pouvourville
Journal:  Eur J Endocrinol       Date:  2007-05       Impact factor: 6.664
  9 in total
  1 in total

1.  Influence of the first radioactive iodine ablation on peripheral complete blood count in patients with differentiated thyroid cancer.

Authors:  Tianpeng Hu; Zhaowei Meng; Guizhi Zhang; Qiang Jia; Jian Tan; Wei Zheng; Renfei Wang; Xue Li; Na Liu; Pingping Zhou; Arun Upadhyaya
Journal:  Medicine (Baltimore)       Date:  2016-08       Impact factor: 1.889
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.